US Patent Issued to Pfizer on Feb. 3 for "Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor" (California Inventors)

ALEXANDRIA, Va., Feb. 3 -- United States Patent no. 12,539,304, issued on Feb. 3, was assigned to Pfizer Inc. (New York).

"Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor" was invented by Ping Wei (San Diego) and Scott Lawrence Weinrich (San Diego).

According to the abstract* released by the U.S. Patent & Trademark Office: "This invention relates to combination therapies comprising an inhibitor of anaplastic lymphoma kinase (ALK) and, an inhibitor of cyclin dependent kinase 4 and 6 (CDK4/6 inhibitor) or an inhibitor of cyclin dependent kinase 2, 4 and 6 (CDK2/4/6 inhibitor), and associated methods of treatment, combinations, pharmaceutical compositions and uses thereof."

The patent was filed...